文献速递白血病

正常核型且无NPM1突变或FLT3-ITD的急性髓系白血病突变图谱与风险分层

Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD).
PubMed 文献 · Br J Haematol · 2020-02-26

该研究纳入158例正常核型且无NPM1突变或FLT3-ITD的新诊断成人AML患者,均在两周期诱导治疗后达完全缓解,并接受有无异基因移植的两种缓解后策略。靶向测序多因素分析显示,CEBPA野生型或单等位突变、NRAS突变、CSF3R突变及第二巩固周期后MRD阳性与复发累积发生率及生存独立相关。具有至少一个不良风险因素的患者从移植中获益,其余患者未获益。

要点

  • CEBPA野生型或单等位突变、NRAS突变、CSF3R突变及第二巩固周期后MRD阳性提示高复发风险。
  • 具有至少一个上述不良风险因素的患者接受异基因移植可获益。
  • 无上述不良风险因素的患者未从移植中获益。

核心结论

  • 在正常核型且无NPM1突变或FLT3-ITD的AML中,CEBPA野生型或单等位突变、NRAS突变、CSF3R突变及第二巩固周期后MRD阳性与更高的复发累积发生率和更差生存独立相关。
  • 具有至少一个上述不良风险因素的患者从异基因移植中获益,而无这些因素的患者未获益。

研究设计与样本

  • 研究纳入158例新诊断成人AML患者,均为正常核型且无NPM1突变或FLT3-ITD,且在两个诱导周期内达到组织学完全缓解。
  • 患者被分配至接受或不接受异基因移植的两种缓解后策略,诊断时进行靶向区域测序,数据用于评估复发和生存预后。

临床怎么用

  • 对正常核型且无NPM1突变或FLT3-ITD的AML患者,可检测CEBPA、NRAS、CSF3R突变及第二巩固周期后MRD以进行风险分层。
  • 具有至少一个上述不良风险因素的患者可能从异基因移植中获益,而无这些因素的患者未显示移植获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

About 25% of patients with newly diagnosed acute myeloid leukaemia (AML) have normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). The prognosis and best therapy for these patients is controversial. We evaluated 158 newly diagnosed adults with this genotype who achieved histological complete remission within two cycles of induction therapy and were assigned to two post-remission strategies with and without an allotransplant. Targeted regional sequencing at diagnosis was performed and data were used to estimate their prognosis, including relapse and survival. In multivariable analyses, having wild-type or mono-allelic mutated CCAAT/enhancer-binding protein alpha (CEBPA) [hazard ratio (HR) 2·39, 95% confidence interval (CI) 1·08-5·30; P = 0·032), mutated NRAS (HR 2·67, 95% CI 1·36-5·25; P = 0·004), mutated colony-stimulating factor 3 receptor (CSF3R) (HR 2·85, 95% CI 1·12-7·27; P = 0·028) and a positive measurable residual disease (MRD)-test after the second consolidation cycle (HR 2·88, 95% CI 1·32-6·30; P = 0·008) were independently correlated with higher cumulative incidence of relapse (CIR). These variables were also significantly associated with worse survival (HR 3·02, 95% CI 1·17-7·78, P = 0·022; HR 3·62, 95% CI 1·51-8·68, P = 0·004; HR 3·14, 95% CI 1·06-9·31, P = 0·039; HR 4·03, 95% CI 1·64-9·89, P = 0·002; respectively). Patients with ≥1 of these adverse-risk variables benefitted from a transplant, whereas the others did not. In conclusion, we identified variables associated with CIR and survival in patients with AML and normal cytogenetics without a NPM1 mutation or FLT3-ITD.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhou YL, Wu LX, Peter Gale R, et al. Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). Br J Haematol. 2020. PMID: 32103499. doi:10.1111/bjh.16526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。